Heparanase up-regulation in tongue cancer: Tissue and saliva analysis

Cancer

Volumn 110, Issue 12, 2007, Pages 2732-2739

  Nagler, Rafael M ^a,b   Ben Izhak, Ofer ^a   Cohen Kaplan, Victoria ^a   Shafat, Itay ^a   Vlodavsky, Israel ^a   Akrish, Sharon ^a   Ilan, Neta ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Oral and Maxillofacial Surgery Department   (Israel)

Author keywords

Bcl 2; Heparanase; P27; Skp 2; Tongue cancer

Indexed keywords

HEPARANASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVA ANALYSIS; TONGUE CANCER; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION;

AGED; DISEASE PROGRESSION; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SALIVA; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; UP-REGULATION;

EID: 37049031523     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23095     Document Type: Article

References (49)

1. Kantola S, Parikka M, Jokinen K, et al. Prognostic factors in tongue cancer - relative importance of demographic, clinical and histopathological factors. Br J Cancer. 2000;83:614-619.
2. Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes, Otolaryngol Head Neck Surg. 2000;122:44-51.
3. Alho OP, Kantola S, Pirkola U, Laara E, Jokinen K, Pukkala E. Cancer of the mobile tongue in Finland - increasing incidence, but improved survival. Acta Oncol. 1999;38:1021-1024.
4. Ribeiro KC, Kowalski LP, Latorre MR. Impact of comorbidity, symptoms, and patients' characteristics on the prognosis of oral carcinomas. Arch Otolaryngol Head Neck Surg. 2000;126:1079-1085.
5. Yeole BB, Sankaranarayanan R, Sunny M Sc L, Swaminathan R, Parkin DM. Survival from head and neck cancer in Mumbai (Bombay), India. Cancer. 2000;89:437-444.
6. Jackson MS, Wrench AA, Soutar DS, Robertson AG. Carcinoma of the tongue: the speech therapist's perspective. Br J Oral Maxillofac Surg. 1999;37:200-204.
7. Nagler RM, Barak M, Ben-Aryeh H, Peled M, Filatov M, Laufer D. Early diagnostic and treatment monitoring role of cyfra 21-1 and tps in oral squamous cell carcinoma. Cancer. 1999;35:1018-1025.
8. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers - a new diagnostic tool for oral cancer. Clin Cancer Res. 2006;12:3979-3984.
9. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341-347.
10. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99-108.
11. Dempsey I, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000;25:349-351.
12. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997;91:439-442.
13. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9:21-32.
14. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 1992;41:391-412.
15. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777.
16. Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A. 1987;84:2292-2296.
17. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res. 1983;43:2704-2711.
18. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL. Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B16 melanoma sublines. Science. 1983;220:611-613.
19. Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem. 1984;259:2283-2290.
20. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst. 2004;96:1219-1230.
21. Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001;61:4655-4659.
22. Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer. J Urol. 2001;166:1286-1290.
23. Tang W, Nakamura Y, Tsujimoto M, et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol. 2002;15:593-598.
24. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003;14:1505-1510.
25. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R. Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia. 2006;9:879-884.
26. Bar Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology. 2006;49:188-193.
27. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia. 2006;8:1055-1061.
28. Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol. 2004;87:174-181.
29. Rohloff J, Zinke J, Schoppmeyer K, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer. 2002;86:1270-1275.
30. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 2003;83:613-622.
31. Ikuta M, Podyma KA, Maruyama K, Enomoto S, Yanagishita M. Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol. 2001;37:177-184.
32. Kurokawa H, Katsube K, Podyma KA, et al. Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts. Cancer Sci. 2003;94:277-285.
33. Ben Izhak O, Kablan F, Laster Z, Nagler RM. Oropharyngeal cancer pathogenesis: ubiquitin proteolytic, apoptotic and epidermal growth factor related pathways act in concert - first report. Oral Oncol. 2005;41:851-860.
34. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004;117:2249-2258.
35. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun. 2006;341:958-963.
36. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb. 2006;35:116-127.
37. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018-2039.
38. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res. 2001;7:1299-1305.
39. Maxhimer JB, Quiros RM, Stewart R, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery. 2002;132:326-333.
40. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15:1661-1663.
41. Zetser A, Bashenko Y, Miao HO, Vlodavsky I, Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res. 2003;63:7733-7741.
42. Gingis-Velitski S, Zetser A, Kaplan V, et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem. 2004;279:44084-44092.
43. Zcharia E, Zilka R, Yaar A, et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 2005;19:211-221.
44. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455-1463.
45. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost. 2006;4:2443-2451.
46. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, bax, bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer. 1999;86:913-920.
47. Ravi D, Ramaads K, Mathew BS, Valinakumarit KR, Nair MK, Pillai MR. De novo programmed cell death in oral cancer. Histopathology. 1999;34:241-249.
48. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
49. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C. The cell cycle inhibitor p27 is an independent prognostic marker in small (t1a,b) invasive breast carcinomas. Cancer Res. 1997;57:1259-1263.